Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
UCART-22 by Cellectis for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
UCART-22 is under clinical development by Cellectis and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...
Risk adjusted net present value: What is the current valuation of Cellectis's UCART-22?
UCART-22 is a gene-modified cell therapy commercialized by Cellectis, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia...
Risk adjusted net present value: What is the current valuation of Cellectis's UCART-22?
UCART-22 is a gene-modified cell therapy commercialized by Cellectis, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia...